Rubicon Deep-Dive
Therapy Area Explorer

Therapy Area Explorer

Therapy-level market structure across India and regulated markets — size, growth, chronicity, pricing power, competition and where Rubicon's pipeline plays.

Modeled estimates
What this shows

Breaks the market down by disease area (cardiac, diabetes, CNS, oncology…) — how big each is, how fast it's growing, and how much pricing power companies have there.

How to use it

Each card is one therapy area, sorted by growth. Violet-ringed cards are areas where Rubicon's pipeline is active. Use it to see which disease categories are most attractive to compete in.

Key terms
Chronicity
— Whether the illness is chronic (long-term, recurring revenue) or acute (one-off treatment).
Pricing power
— How freely companies can price — limited where NLEM price controls apply.
CNS
— Central Nervous System — neurology/psychiatry drugs (ADHD, migraine, etc.), a Rubicon focus.

Oncology

15% growth
Market size
₹9,000 cr
Chronicity
Specialty
Pricing power
Low
Competition
Medium
Leaders
Sun, DRL, Cipla, Zydus
Rubicon relevance
Low

Dermatology

13% growth
Market size
₹13,500 cr
Chronicity
Mixed
Pricing power
Low
Competition
Medium
Leaders
Sun, Glenmark, Cipla
Rubicon relevance
Specialty optionality

Diabetes / Anti-diabetic

12% growth
Market size
₹22,000 cr
Chronicity
Chronic
Pricing power
Medium
Competition
High
Leaders
USV, Sun, Mankind, Abbott
Rubicon relevance
Cardio-metabolic pipeline

CNS / Neuro-psychiatry

12% growth
Market size
₹13,000 cr
Chronicity
Chronic
Pricing power
Low
Competition
Medium
Leaders
Sun, Intas, Lupin
Rubicon relevance
ADHD, migraine, transdermal — core

Ophthalmology

12% growth
Market size
₹4,500 cr
Chronicity
Mixed
Pricing power
Low
Competition
Medium
Leaders
Sun, Cipla, Entod
Rubicon relevance
Pipeline optionality

Cardiac

11% growth
Market size
₹28,000 cr
Chronicity
Chronic
Pricing power
Medium
Competition
High
Leaders
Sun, Torrent, USV, Cipla
Rubicon relevance
Icosapent ethyl

Gastro-intestinal

10% growth
Market size
₹19,000 cr
Chronicity
Mixed
Pricing power
Medium
Competition
High
Leaders
Abbott, Alkem, Sun
Rubicon relevance
Budesonide

Gynaecology

10% growth
Market size
₹11,000 cr
Chronicity
Mixed
Pricing power
Medium
Competition
High
Leaders
Abbott, Mankind, Sun
Rubicon relevance
Low

Respiratory

9% growth
Market size
₹16,000 cr
Chronicity
Mixed
Pricing power
Medium
Competition
High
Leaders
Cipla, Lupin, Glenmark
Rubicon relevance
Selective

Vitamins / Nutrients

9% growth
Market size
₹18,000 cr
Chronicity
Acute
Pricing power
Low
Competition
Very High
Leaders
Abbott, Mankind, Sun
Rubicon relevance
Low

Pain / Analgesics

8% growth
Market size
₹14,000 cr
Chronicity
Acute
Pricing power
High (NLEM)
Competition
Very High
Leaders
Sun, Abbott, Cipla
Rubicon relevance
Low

Anti-infectives

6% growth
Market size
₹21,000 cr
Chronicity
Acute
Pricing power
High (NLEM)
Competition
Very High
Leaders
Alkem, Mankind, Cipla
Rubicon relevance
Low